Eunice Ann Wong, MD
Infectious Disease · Columbia, MONPI 1386928489
Payments from drug & device makers
Across 25 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$160
- Merck$120
- GE HealthCare$62
- La Jolla Pharmaceutical Company$58
- Shionogi Inc$44
- Melinta Therapeutics, LLC$24
- plus $89 from 5 others
What the payments were for
- Food & beverage$45982%
- Education$9818%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 6 | $160 |
| Merck | 7 | $120 |
| GE HealthCare | 1 | $62 |
| La Jolla Pharmaceutical Company | 3 | $58 |
| Shionogi Inc | 2 | $44 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| AbbVie | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$557 in reported general payments places this provider in the 55th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $55,369 |
| Daptomycin | 11 | $4,644 |
| CeftriaxoneCeftriaxone Sodium | 26 | $3,572 |
| Vancomycin Hcl | 21 | $2,656 |
| Cefepime Hcl | 14 | $1,553 |
| Doxycycline Hyclate | 35 | $984 |
| Linezolid | 12 | $683 |
| Cefazolin Sodium | 11 | $648 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $352 |
| Ciprofloxacin Hcl | 17 | $159 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $149 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Columbia
- Phillip BeckColumbia$7K
- Amy BowersColumbia$1K
- Rachel PrestiSaint Louis$2.7M
- Sarah GeorgeSaint Louis$1.8M
- Michael DiamondSaint Louis$1.7M
- Andrej SpecSaint Louis$1.6M
- Erik DubberkeSaint Louis$1M
- Sharon FreySaint Louis$702K
- Daniel HoftSt Louis$573K
- Robert BelsheSaint Louis$382K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.